Drug Trial Radar · NCT06611371
Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Actual
Start
Nov 12, 2024
Primary completion
Aug 26, 2025
Study completion Feb 2026
Sponsor
- Lead sponsor
- Inventprise Inc.Industry
- Sponsor type
- Industry
- Collaborators
- PATH
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess the safety and tolerability of IVT GBS-06 vaccine administered as a single-dose regimen, at three dosage levels in healthy, non-pregnant, adult women of childbearing age (WOCBA).
Conditions
- Group B Streptococcal Infections
Interventions
IVT GBS-06Biological
Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, III, V, and VII) administered as a single dose.
PlaceboBiological
0.9% sodium chloride
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety -percentage of participants reporting immediate AE within 30 minutes of vaccinationTime frame: 30 minutes after vaccination
- Safety - percentage of participants reporting solicited local adverse events (AEs) within 7 days of vaccinationTime frame: Day 1 - Day 7 after vaccination
- Safety- percentage of participants reporting solicited systemic AEs within 7 days following study vaccination (fever, fatigue, headache, chills, myalgia, arthralgia, and nausea/vomiting)Time frame: Day 1 - Day 7 after vaccination
- Safety - percentage of participants reporting unsolicited AEs within 28 days following study vaccinationTime frame: Day 1 - Day 28 after vaccination
- Safety - percentage of participants with clinically significant laboratory abnormalities within 7 days following study vaccinationTime frame: Day 1 - Day 7 after vaccination
- Safety - percentage of participants reporting medically attended adverse events (MAAEs)Time frame: From Day 1 vaccination through the end of study
- Safety - percentage of participants reporting serious adverse events (SAEs)Time frame: From Day 1 vaccination through the end of study
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
NYU Grossman School of Medicine
New York, New York
Wits Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), University of the Witwatersrand
Johannesburg, Gauteng, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.